Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Jazz Pharmaceuticals
Biotech
Jazz pays $820M to add epilepsy-focused Actio to its orchestra
Jazz Pharmaceuticals is adding to its orchestra of epilepsy treatments with the acquisition of Actio Biosciences for $820 million upfront.
Will Maddox
Aug 10, 2026 10:40am
Jazz, AbCellera strike TCE discovery and development deal
Jun 17, 2026 7:00am
Takeda inks $1.7B AI discovery deal with Iambic Therapeutics
Feb 9, 2026 8:00am
Former Roche oncology head turns to Tubulis—Chutes & Ladders
Jan 9, 2026 8:30am
Jazz pays Saniona $42.5M to add prospect to epilepsy ensemble
Aug 20, 2025 9:13am
Pfizer’s reputation wrangler plans departure—Chutes & Ladders
Jul 11, 2025 8:30am
